A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HS248 in the Treatment of Patients With Advanced Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- HS248 pieces
- Conditions
- Solid Tumor, Adult
- Sponsor
- Hanhui Pharmaceutical Co., Ltd
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Safety and tolerability
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This study is a non-random, open multi-center study This study is a non-random, open multi-center phase I study, aimed at evaluation period research, aimed at In the evaluation phase study, it aims to evaluate the safety, tolerance PK characteristics and preliminary anti-tumor activity of HS248 in patients with advanced solid tumors. The study was divided into 2 phases, including dose escalation and dose expansion。
Detailed Description
Main purpose: Assess the safety and tolerability of HS248 in patients with advanced solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of HS248. Secondary purpose: Secondary purpose: Assess the pharmacokinetic (PK) profile of HS248 in patients with advanced solid tumors; To evaluate the preliminary antitumor activity of HS248 in patients with advanced solid tumors. Preliminary antitumor activity in patients with advanced solid tumors. Other purposes: Population-based PK (PopPK) analysis method, exploratory description) analysis method, exploratory description) analysis method, exploratory description) analysis method, exploratory description of HS248 in patients with advanced solid tumors PK features in; Evaluate the relationship between exposure and efficacy and adverse events (AEs) of HS248 in patients with advanced solid tumors, as data permit; To explore the changes of HS248 in myeloid-derived suppressor cells (MDSC) and CD8+ T cells in patients with advanced solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Voluntarily participate in this clinical trial, understand and follow the research procedures and voluntarily sign the ICF;
- •Male or female, age ≥18 when signing the ICF;
- •Expected survival period ≥ 12 weeks;
- •Patients with advanced solid tumors confirmed by histology/cytology, who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment plan (patients with multiple solid tumors are included in the dose-escalation phase, and the population included in the dose-expansion phase will be based on dose escalation phase study data and the potential advantageous population of similar drugs);
- •Eastern Cooperative Oncology Group (ECOG) physical status score 0-1
Exclusion Criteria
- •Symptomatic or untreated central nervous system metastasis or primary central nervous system malignancy;
- •Other known malignant tumors in the past 5 years, except cured localized tumors, including carcinoma in situ of the cervix, basal cell carcinoma of the skin, and carcinoma in situ of the prostate;
- •Previous history of autoimmune diseases, stem cell transplantation or organ transplantation;
- •Known drug-induced liver injury, chronic active hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, persistent extrahepatic obstruction caused by gallstones, cirrhosis or portal hypertension;
- •Peptic ulcer and/or gastrointestinal bleeding at present or in the past;
- •Gastrointestinal dysfunction that may limit the absorption of the test drug, including motility disorders, malabsorption syndrome or inflammatory bowel disease;
Arms & Interventions
HS248 pieces
dose escalation period： At this stage, it is planned that HS248 will adopt the traditional "3+3" method of increasing doses at four dose levels of 20 mg, 40 mg, 60 mg and 80 mg. All dosage components are divided into single administration stage and multiple administration stage. After 5 days of observation after single administration, it enters the stage of multiple administration. In the stage of multiple administration, HS248 is administered once a day (qd) for 28 days. a treatment cycle. 33 days after the first administration (the 5-day observation period in the single-administration phase and the first cycle in the multiple-administration phase) is the dose-limiting toxicity (DLT) observation period of this study
Intervention: HS248 pieces
Outcomes
Primary Outcomes
Safety and tolerability
Time Frame: From first dose of HS248 through 28 days after the last HS248 treatment (up to 2 years); each cycle is 28 days
To examine the incidence of clinical and laboratory adverse events after multiple doses of HS-248 in the dose escalation and dose expansion phases
MTD and/or RP2DP2D
Time Frame: The end of the study is defined as the last subject completing the last visit, study treatment for 2 years, loss to follow-up, death or withdrawal of informed consent, whichever occurs first
MTD and/or RP2DP2D
Secondary Outcomes
- Peak Plasma Concentration (Cmax)(From date of initial dose until up to 33 days for treatment)
- Area Under the Plasma Concentration versus Time Curve (AUC)(From date of initial dose until up to 33 days for treatment)
- ORR(Up to 2 years)
- DOR(Up to 2 years)
- PFS(Up to 2 years)
- DCR(Up to 2 years)
- OS(Up to 2 years)